PHARMACEUTICAL COMPOSITIONS COMPRISING COMBINED ANTIDIABETIC SUBSTANCES FOR USE IN DIABETES MELLITUS
申请人:ESPINOZA ABDALA, Leopoldo de Jesús
公开号:EP1935424A1
公开(公告)日:2008-06-25
The present invention relates to the pharmaceutical industry in general and, in particular, to the pharmaceutical industry involved in the preparation of medicaments for controlling diabetes. More specifically, the invention relates to a composition comprising different types of antidiabetic substances in combination. The composition is characterized in that the aforementioned combination or association consists of two or three antidiabetic substances that are selected from the group containing: sulfonylureas, meglitinides, biguanides or inhibitors of alpha-glucosidase with thiazolidinediones for the treatment of type 2 diabetes mellitus in novel formulations and wherein the sulfonylureas are selected from the group containing glipizide, glyburide, glimepiride; meglitinides, repaglinide, nateglinide, thiazolidinediones or a combination of same; biguanides such as metformin; inhibitors of alpha-glucosidase known as acarbose, miglitol associated or combined with thiazolidinediones known as pioglitazone, rosiglitazone, troglitazone, such as a base or a physiologically-accepted salt.
本发明涉及整个制药行业,特别是涉及制备控制糖尿病药物的制药行业。更具体地说,本发明涉及一种由不同类型的抗糖尿病物质组合而成的组合物。该组合物的特征在于,上述组合或联合物由两种或三种抗糖尿病物质组成,这些抗糖尿病物质选自以下组别:磺脲类、甲巯咪唑类、吲哚美辛类、吲哚美辛类和吲哚美辛类:磺脲类、梅格列酮类、双胍类或α-葡萄糖苷酶抑制剂与噻唑烷二酮类,用于治疗新型制剂中的 2 型糖尿病,其中磺脲类药物选自包含格列吡嗪、甘布脲、格列美脲、梅格列酮、雷帕吉特的组;美格列奈、瑞格列奈、纳格列奈、噻唑烷二酮类或其复方制剂;双胍类,如二甲双胍;α-葡萄糖苷酶抑制剂,如阿卡波糖、米格列醇,与噻唑烷二酮类,如吡格列酮,罗格列酮,曲格列酮,如碱基或生理上可接受的盐相关联或复方制剂。